Veliparib + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Metastases From Non-small Cell Lung Cancer
Conditions
Brain Metastases From Non-small Cell Lung Cancer
Trial Timeline
Oct 19, 2012 → Jan 22, 2015
NCT ID
NCT01657799About Veliparib + Placebo
Veliparib + Placebo is a phase 2 stage product being developed by AbbVie for Brain Metastases From Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01657799. Target conditions include Brain Metastases From Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01657799 | Phase 2 | Completed |
Competing Products
20 competing products in Brain Metastases From Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 52 |
| GLIADEL | Eisai | Phase 2 | 52 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 33 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| ABT-888 | AbbVie | Phase 1 | 33 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 52 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 52 |
| Exenatide | AstraZeneca | Approved | 85 |
| AZD5213 | AstraZeneca | Phase 1 | 33 |
| Vorinostat | Merck | Phase 1 | 33 |